Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatorycells

Cellular and Molecular Immunology

Volumn 7, Issue 2, 2010, Pages 157-162

  Liu, Rongjun ^a   Xiong, Shudao ^a   Zhang, Lei ^a   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CD4 +CD44+ CD8+CD44+ effector memory T cells; CD4+CD25+Foxp3+ T cells; Low dose total body irradiation; LTBI; Tumor vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; WHOLE BODY RADIATION;

ANIMALS; CANCER VACCINES; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; WHOLE-BODY IRRADIATION;

MUS;

EID: 77749252468     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.117     Document Type: Article

References (24)

1. Maine GN, Mule JJ. Making room for T cells. J Clin Invest 2002; 110: 157-159.
2. Berk LB, HoDes PJ. Roentgen therapy for infections: an historical review. Yale J Biol Med 1991; 64: 155-165.
3. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170: 6338-6347.
4. Kaufman HL, Divgi CR. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. Clin Cancer Res 2005; 11: 6757-6762.
5. Ge Q, Hu H, Eisen HN, Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Natl Acad Sci USA 2002; 99: 2989-2994.
6. Min B, Paul WE. Endogenous proliferation: burst-like CD4 T cell proliferation in lymphopenic settings. Semin Immunol 2005; 17: 201-207.
7. Palucka AK, Ueno H, Fay J, Banchereau J. Dendritic cells: a critical player in cancer therapy?; J Immunother 2008; 31: 793-805.
8. Yu P, Lee Y, Liu W, Krausz T, Chong A, SchreiberHet al. Intratumor Depletion of CD41 cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791.
9. Lin Y, Xiong S, Zhang L, Zhang Y, Cai Y, Xu L et al. Big tumor regression induced by GMCSF gene-modified 3LL tumor cells via facilitating DC maturation and Deviation toward CD11c1CD8alpha1 subset. DNA Cell Biol 2007; 26: 863-872.
10. Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R et al. Efficacy of GM-CSFproducing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 2006; 29: 367-380.
11. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ et al. Mesothelin-specific CD8(1) T cell responses proviDe eviDence of in vivo crosspriming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306.
12. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al. Recruitment of latent pools of high-avidity CD8(1) T cells to the antitumor immune response. J Exp Med 2005; 201: 1591-1602.
13. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamiDe for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14: 1455-1463.
14. Mule JJ, Jones FR, Hellstrom I, Hellstrom KE. Selective localization of radiolabeled immune lymphocytes into syngeneic tumors. J Immunol 1979; 123: 600-606.
15. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphoDepletion and adoptive immunotherapy. J Immunol 2004; 172: 3462-3468.
16. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H et al. Accelerated memory cell homeostasis during T cell Depletion and approaches to overcome it. J Immunol 2006; 176: 4632-4639.
17. Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol 2000; 164: 2338-2346.
18. Veiga-FernanDes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD81 T cells to antigen stimulation in vivo. Nat Immunol 2000; 1: 47-53.
19. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-855.
20. Wang RF. Immune suppression by tumor-specific CD41 regulatory T-cells in cancer. Semin Cancer Biol 2006; 16: 73-79.
21. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al. CD41CD251 regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamiDe which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336-344.
22. Liu JY,WuY, Zhang XS, Yang JL, Li HL, Mao YQ et al. Single administration of low dose cyclophosphamiDe augments the antitumor effect of Dendritic cell vaccine. Cancer Immunol Immunother 2007; 56: 1597-1604.
23. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol. 2008; 129: 219-229.
24. Cuttler JM, Pollycove M. Nuclear energy and health: and the benefits of low-dose radiation hormesis. Dose Response 2009; 7: 52-89.